Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isis Builds On Platform Strategy With Fourth Biogen Tie-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.

You may also be interested in...



Biopharma Dealmaking Quarterly Statistics, Q3 2013

Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.

Deals of the Week Watches Parkinson’s In Prime Time

Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.

Deals of the Week Watches Parkinson’s In Prime Time

Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel